Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer

Next Previous
X
Search
Trial Profile

A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Cyclophosphamide; Epirubicin; Exemestane; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Paclitaxel; Tamoxifen
  • Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms TP-II

    • Most Recent Events

    • 16 Apr 2024 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2023 Results of translational pre-planned analysis assessing associations of gene expression signatures and sTILs with pCR presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2020 Primary endpoint has been met. (Pathological complete response (pCR))

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top